Answers are grounded in this paper and cite their sources.
Objective: Peroxisome proliferator-activated receptor (PPAR) is aberrantly expressed in most breast tumors, suggesting the potential of agents that target this receptor in treatment and chemoprevention of breast cancer. However, whether PPAR leads to the promotion or reduction of tumor formation has remained controversial and is further complicated by the ability of its available thiazolidinedione (TZD) ligands to activate another PPAR subtype, PPAR.
No takes yet. Share an insight, caveat, or question.
Hall JM Robinson ML (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: